Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Thumbnail

After pressure from SNMMI, Aetna expands coverage of gallium-68 dotatate PET

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced this week that Aetna has expanded its coverage of gallium-68 (Ga-68) dotatate PET.

Thumbnail

SNMMI highlights gallium-68 shortage in letter to FDA

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has written a letter to the FDA about ongoing shortages of generators that produce gallium-68 (Ga-68), a radioisotope used regularly in medical imaging.

SNMMI recognizes 2018 award winners

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) recognized numerous award winners throughout its 2018 Annual Meeting in Philadelphia.

SNMMI-TS names 2018 award winners

This year, the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS) honored numerous technologists with awards for contributions to the fields of nuclear medicine and molecular imaging.

Thumbnail

Normal E. Bolus elected 2018-2019 president of SNMMI-TS

Norman E. Bolus, MSPH, MPH, CNMT, was elected 2018-2019 president of the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS) at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2018 Annual Meeting in Philadelphia.

Thumbnail

Satoshi Minoshima elected SNMMI president during annual meeting

Satoshi Minoshima, MD, PhD, officially assumed office as 2018-2019 president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) at the SNMMI 2018 Annual Meeting in Philadelphia.

Thumbnail

SNMMI recommends Aetna reverse 2 PET coverage decisions

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued a statement recommending Aetna reverse its decision not to cover the use of gallium Ga 68 dotatate PET or fluciclovine F18 PET for treating cancer patients.

SNMMI publishes AUC for somatostatin receptor PET imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced Thursday, Jan. 4, the publication of appropriate use criteria (AUC) for somatostatin receptor PET imaging in neuroendocrine tumors.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The all-in-one Omni Legend PET/CT scanner is now being manufactured in a new production facility in Waukesha, Wisconsin.